MB
Therapeutic Areas
Applied Tissue Technologies Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PWD for NPWT (Phase II Enhancement) | Incisional Wounds | Phase 2 |
| PWD for Ocular & Periocular Injuries | Ocular Injuries, Infections, and Periocular Burns | Clinical Trial |
Leadership Team at Applied Tissue Technologies
EE
Elof Eriksson, MD, PhD
Chief Medical Officer, Founder
KN
Kristo Nuutila, MSc, PhD
Director of Research